Brief: Almirall Says FDA Approves Klisyri For Actinic Keratosis Treatment On Expanded Areas
10/06/2024 07:09
June 10 (Reuters) - Almirall SA ALM.MC :
* FDA APPROVES KLISYRI (TIRBANIBULIN) FOR TREATMENT OF
ACTINIC
KERATOSIS ON EXPANDED AREA OF FACE OR SCALP UP TO 100 CM2
Source text for Workspace: ID:nCNM4dwBFR
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24